Gastric Cancer (GC)NCT07332104
The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases
An observational study of Gastric Cancer (GC) and Gastric Cancer (Diagnosis), run by Beijing Friendship Hospital.
Trial summary
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. Read more about this study
- Who is it for?
- Ages 40 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Gastric Cancer (GC), Gastric Cancer (Diagnosis)
- What is being tested?
- In vitro surface plasmon resonance detection
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Dec 2025to 15 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Gastric cancer and non-cancer patients
Who may be able to join
- Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.
- Previous gastroscopy suggested the possibility of lesions.
- No previous history of gastrointestinal cancer.
Who cannot join
- Patients could not cooperate with the examination or had contraindications to endoscopy.
- Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.
- Severe bile reflux.
- Take simethicone and other defoaming agents before examination.
- Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.
- Conditions
- Gastric Cancer (GC), Gastric Cancer (Diagnosis)
- Being tested
- In vitro surface plasmon resonance detection
- Keywords
- Gastric cancer, Extracellular vesicles
- Medical subject headings
- Stomach Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In vitro surface plasmon resonance detectionDiagnostic test
Gastric juice from patients was removed for isolation of extracellular vesicles and surface plasmon resonance detection in vitro
| Study group | Role | What they receive |
|---|---|---|
| gastric cancer | Patients diagnosed with gastric cancer Receives: Diagnostic Test: In vitro surface plasmon resonance detection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surface plasmon resonance(SPR) detection of extracellular vesicles in gastric juice of patients with gastric cancer has large shift and spectral changes
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start15 Dec 2025 (estimated)
- Primary completion15 Dec 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric Cancer (GC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Friendship Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Li, Beijing Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07332104
- Sponsor's protocol ID
- BFHZS20240020
- Other IDs
- No. BFHZS20240020
- Status last verified
- Dec 2025
- First submitted
- 14 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No